Tags

Type your tag names separated by a space and hit enter

Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.
Paediatr Drugs. 2011 Jun 01; 13(3):197-204.PD

Abstract

Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability subscale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score. Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months.

Authors+Show Affiliations

Adis, a Wolters Kluwer Business, Auckland, New Zealand. demail@adis.co.nz

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

21500873

Citation

Curran, Monique P.. "Aripiprazole: in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Patients." Paediatric Drugs, vol. 13, no. 3, 2011, pp. 197-204.
Curran MP. Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatr Drugs. 2011;13(3):197-204.
Curran, M. P. (2011). Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatric Drugs, 13(3), 197-204. https://doi.org/10.2165/11207230-000000000-00000
Curran MP. Aripiprazole: in the Treatment of Irritability Associated With Autistic Disorder in Pediatric Patients. Paediatr Drugs. 2011 Jun 1;13(3):197-204. PubMed PMID: 21500873.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. A1 - Curran,Monique P, PY - 2011/4/20/entrez PY - 2011/4/20/pubmed PY - 2011/11/16/medline SP - 197 EP - 204 JF - Paediatric drugs JO - Paediatr Drugs VL - 13 IS - 3 N2 - Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability subscale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score. Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months. SN - 1179-2019 UR - https://www.unboundmedicine.com/medline/citation/21500873/Aripiprazole:_in_the_treatment_of_irritability_associated_with_autistic_disorder_in_pediatric_patients_ L2 - https://dx.doi.org/10.2165/11207230-000000000-00000 DB - PRIME DP - Unbound Medicine ER -